These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18395136)

  • 1. Fabry disease--whom to treat and when.
    Mehta A
    Clin Ther; 2008; 30 Suppl B():S43-4. PubMed ID: 18395136
    [No Abstract]   [Full Text] [Related]  

  • 2. Fabry disease in an oligosymptomatic male.
    Altarescu G; Elstein D
    Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
    [No Abstract]   [Full Text] [Related]  

  • 3. [Fabry disease: new clinical research--current therapeutic perspectives].
    Beck M
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
    [No Abstract]   [Full Text] [Related]  

  • 4. Pediatrics: implementing the promise of early intervention for Fabry disease.
    Raas-Rothschild A
    Clin Ther; 2007; 29 Suppl A():S6. PubMed ID: 17580239
    [No Abstract]   [Full Text] [Related]  

  • 5. [Intravenous lidocaine as treatment for the painful episodes in Fabry's disease].
    Politei JM
    Rev Neurol; 2009 Aug 1-15; 49(3):166-7. PubMed ID: 19621314
    [No Abstract]   [Full Text] [Related]  

  • 6. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 7. Early detection of Fabry disease: cardiac cases.
    Weidemann F; Strotmann J
    Clin Ther; 2008; 30 Suppl B():S46. PubMed ID: 18395138
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
    Lenders M; Brand E
    J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
    Demontis R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fatal outcome of a patient with Fabry disease in enzymatic treatment].
    Moyano MJ; del Toro N; Amor J; Milán JA
    Nefrologia; 2005; 25(2):207-8. PubMed ID: 15912661
    [No Abstract]   [Full Text] [Related]  

  • 11. Peripheral nervous system involvement in Fabry disease: role in morbidity and mortality.
    Hilz MJ
    Clin Ther; 2007; 29 Suppl A():S11-2. PubMed ID: 17580234
    [No Abstract]   [Full Text] [Related]  

  • 12. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
    Martin-Suárez I; Suárez-Marrero C
    Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
    [No Abstract]   [Full Text] [Related]  

  • 13. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
    Wanner C
    Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
    [No Abstract]   [Full Text] [Related]  

  • 14. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzyme replacement in Anderson-Fabry disease.
    Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
    Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
    [No Abstract]   [Full Text] [Related]  

  • 16. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement in Fabry disease: the essence is in the kidney.
    Schiffmann R
    Ann Intern Med; 2007 Jan; 146(2):142-4. PubMed ID: 17179053
    [No Abstract]   [Full Text] [Related]  

  • 18. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
    Banikazemi M; Desnick RJ
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
    Hollak CE; Linthorst GE
    Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
    [No Abstract]   [Full Text] [Related]  

  • 20. Agalsidase beta (Fabrazyme) for Fabry disease.
    Med Lett Drugs Ther; 2003 Sep; 45(1165):74-5. PubMed ID: 12968124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.